Literature DB >> 28264798

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial.

Pier Luigi Zinzani1, Cinzia Pellegrini1, Annalisa Chiappella2, Alice Di Rocco3, Flavia Salvi4, Maria Giuseppina Cabras5, Lisa Argnani1, Vittorio Stefoni1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28264798     DOI： 10.1182/blood-2017-01-764258

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

1.  Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Authors:  Pier Luigi Zinzani; Vincent Ribrag; Craig H Moskowitz; Jean-Marie Michot; John Kuruvilla; Arun Balakumaran; Yayan Zhang; Sabine Chlosta; Margaret A Shipp; Philippe Armand
Journal:  Blood       Date:  2017-05-10       Impact factor: 22.113

Review 2.  Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies.

Authors:  Kieron Dunleavy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Authors:  Pier Luigi Zinzani; Armando Santoro; Giuseppe Gritti; Pauline Brice; Paul M Barr; John Kuruvilla; David Cunningham; Justin Kline; Nathalie A Johnson; Neha Mehta-Shah; Thomas Manley; Stephen Francis; Manish Sharma; Alison J Moskowitz
Journal:  J Clin Oncol       Date:  2019-08-09       Impact factor: 44.544

Review 4.  How I treat primary mediastinal B-cell lymphoma.

Authors:  Lisa Giulino-Roth
Journal:  Blood       Date:  2018-07-05       Impact factor: 22.113

Review 5.  Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.

Authors:  Mark Roschewski; James D Phelan; Wyndham H Wilson
Journal:  Cancer J       Date:  2020 May/Jun       Impact factor: 2.074

Review 6.  Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Authors:  Charlotte Lees; Colm Keane; Maher K Gandhi; Jay Gunawardana
Journal:  Br J Haematol       Date:  2019-02-10       Impact factor: 6.998

Review 7.  AYA Considerations for Aggressive Lymphomas.

Authors:  Gabriela Llaurador; Lisa Giulino-Roth
Journal:  Curr Hematol Malig Rep       Date:  2021-03-16       Impact factor: 3.952

Review 8.  Antibody Therapies for Large B-Cell Lymphoma.

Authors:  Mattia Novo; Elisa Santambrogio; Pio Manlio Mirko Frascione; Delia Rota-Scalabrini; Umberto Vitolo
Journal:  Biologics       Date:  2021-05-18

Review 9.  Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

Authors:  C A van der Weyden; S A Pileri; A L Feldman; J Whisstock; H M Prince
Journal:  Blood Cancer J       Date:  2017-09-08       Impact factor: 11.037

10.  Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.

Authors:  Jakub Svoboda; Steven M Bair; Daniel J Landsburg; Sunita Dwivedy Nasta; Sarah J Nagle; Stefan K Barta; Nadia Khan; Joanne Filicko-O'Hara; Sameh Gaballa; Lauren Strelec; Elise Chong; Sheryl Mitnick; Terease S Waite; Cara King; Hatcher Ballard; Matthew Youngman; James Gerson; John P Plastaras; Amit Maity; Agata M Bogusz; Stacy S Hung; Hisae Nakamura; Reza Nejati; Christian Steidl; Megan Lim; Marco Ruella; Stephen J Schuster
Journal:  Haematologica       Date:  2021-06-01       Impact factor: 11.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.